Difference between revisions of "Denintuzumab mafodotin (SGN-CD19A)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Antibody medications" to "") Tags: mobile edit mobile web edit |
|||
Line 9: | Line 9: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
− | + | ||
[[Category:Antibody-drug conjugates]] | [[Category:Antibody-drug conjugates]] | ||
[[Category:Anti-CD19 antibodies]] | [[Category:Anti-CD19 antibodies]] |
Revision as of 19:30, 27 February 2020
Mechanism of action
Antibody-drug conjugate
Preliminary studies
- Abstract: Andres Forero-Torres, Craig Moskowitz, Ranjana H. Advani, Bijal D. Shah, Ana Kostic, Tina M. Albertson, Larissa Sandalic, Baiteng Zhao, Michelle A. Fanale. Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL). J Clin Oncol 32:5s, 2014 (suppl; abstr 8505) link to original abstract